Axsome Therapeutics (19X) Price & Analysis

5 Followers

19X Stock Chart & Stats

€179.10

€1.00(0.48%)

At close: Jul 27 4:00 PM EDT

€179.10

€1.00(0.48%)

Day’s Range― - ―

52-Week Range€104.85 - €226.30

Previous CloseN/A

Volume0.00

Average Volume (3M)8.00

Market Cap

€7.54B

Enterprise Value€12.58B

Total Cash (Recent Filing)€319.85M

Total Debt (Recent Filing)€219.21M

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Nov 02, 2026

EPS Estimate

-0.54

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.75

Shares Outstanding52,380,817

10 Day Avg. Volume8

30 Day Avg. Volume8

Financial Highlights & Ratios

PEG Ratio1.29

Price to Book (P/B)102.90

Price to Sales (P/S)14.23

P/FCF Ratio-96.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€254.40

Price Target Upside42.04% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

EPS Forecast (FY)-2.51

Revenue Forecast (FY)€852.76M

Bulls Say, Bears Say

Bulls Say

Strong Commercial Revenue GrowthRapid growth across multiple marketed CNS products indicates that Axsome is building commercial scale rather than relying on a single early-stage asset. Continued prescription expansion and broader product contribution can support stronger operating leverage and a more durable revenue base.

Very High Gross-margin ProfileA gross margin near 93% provides substantial economic value from each additional product sale and creates room to absorb commercial investment. If revenue continues scaling, this margin structure can support improving profitability as selling and development costs grow more slowly than sales.

Regulatory And Pipeline ExpansionFDA acceptance of AXS-12 creates a defined regulatory pathway for another potential CNS product and reduces dependence on the current portfolio alone. A successful review could extend Axsome’s commercial platform and reinforce its position in specialized neuroscience markets.

Bears Say

Persistent Operating And Net LossesAxsome has achieved meaningful revenue growth but has not yet converted that scale into operating or net profitability. Continued losses can constrain reinvestment flexibility and leave future earnings dependent on successful commercialization, cost discipline, and further revenue expansion.

Negative Operating And Free Cash FlowNegative cash generation means the business is still funding operations and expansion without internally generated cash. Although the burn rate has improved, sustained deficits can increase reliance on financing and reduce flexibility to support launches, trials, or unforeseen execution needs.

Elevated Leverage And Thin EquityDebt that substantially exceeds equity creates a less resilient capital structure while the company remains loss-making. Higher leverage can increase financing pressure and restrict capital allocation choices, making balance-sheet improvement or a transition to sustainable profitability important for long-term stability.

Axsome Therapeutics News

Axsome Therapeutics price target lowered to $295 from $297 at RBC Capital

RBC Capital lowered the firm’s price target on Axsome Therapeutics (AXSM) to $295 from $297 and keeps an...

10d ago

AXSM

Axsome Therapeutics price target lowered to $267 from $280 at Deutsche Bank

Deutsche Bank lowered the firm’s price target on Axsome Therapeutics (AXSM) to $267 from $280 and keeps a...

19d ago

AXSM

Axsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Axsome Therapeutics (AXSM) to $247 from $251 and keeps an...

23d ago

AXSM

Axsome Therapeutics assumed with a Buy at Truist

Truist assumed coverage of Axsome Therapeutics (AXSM) with a Buy rating with a price target of $285, up...

25d ago

AXSM

Axsome rises as Mizuho highlights ‘big month-over-month jump’ for Auvelity

Mizuho analyst Graig Suvannavejh reports Bloomberg Symphony prescription data for the 30mg titration dose for Auvelity in ADA...

1M ago

AXSM

Axsome pullback brings attractive entry point, says H.C. Wainwright

H.C. Wainwright keeps a Buy rating on Axsome Therapeutics (AXSM) with a $290 price target after the company...

2M ago

AXSM

Ram Selvaraju Reaffirms Buy on Axsome, Maintaining $290 Price Target Amid Solid Execution and AUVELITY Upside Potential

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on AXSM stock, giving a Buy rating on...

2M ago

AXSM

Axsome Therapeutics price target raised to $316 from $306 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $316 from $306 and...

2M ago

AXSM

Axsome Targets Smoking Cessation With New Phase 3 AXS-05 Trial

Axsome Therapeutics Inc. ($AXSM) announced an update on their ongoing clinical study. The study titled “A Randomized, Double-Blind,...

2M ago

AXSM

Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital

RBC Capital analyst Leonid Timashev lowered the firm’s price target on Axsome Therapeutics (AXSM) to $297 from $304...

2M ago

AXSM

Analyst Reiterates Buy on Axsome, Sees Undervalued Pipeline Upside with Unchanged $310 Price Target

Malcolm Hoffman, an analyst from BMO Capital, maintained the Buy rating on Axsome Therapeutics. The associated price target...

2M ago

AXSM

Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $251 from $242 and keeps an...

2M ago

AXSM

Axsome Therapeutics price target raised to $275 from $260 at Guggenheim

Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $275 from $260 and keeps a Buy...

2M ago

AXSM

Auvelity Momentum and Pipeline Progress Drive Undervalued Upside in Axsome, Supporting Buy Rating

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on AXSM stock, giving a Buy...

2M ago

AXSM

19X FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was €104.85 and its highest was €226.30 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is €7.54B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Nov 02, 2026 which is in 15 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on Aug 10, 2026. The company reported -€0.881 earnings per share for the quarter, missing the consensus estimate of -€0.794 by -€0.087.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.54.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 52,380,817 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -€0.881 in its last earnings report, missing expectations of -€0.794. Following the earnings report the stock price went up 3.077%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in DE:19X

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-255.60%

Trailing 12-Months

Asset Growth

19.02%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Axsome Therapeutics (19X) Earnings & Revenues

Historic Earnings Reports

19X Company Deck

19X Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong positive momentum across Axsome’s commercial portfolio, with 46% revenue growth, accelerating AUVELITY demand, encouraging early Alzheimer’s disease agitation launch metrics, continued SYMBRAVO and SUNOSI prescription growth, improving payer coverage, and substantial pipeline progress. The company remains loss-making, reported higher SG&A and ongoing cash burn, and acknowledged that several Alzheimer’s disease agitation launch metrics are still early and limited. Overall, the highlights significantly outweighed the lowlights.View all DE:19X earnings summaries

19X Stock 12 Month Forecast

Average Price Target

€254.40

▲(42.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"100":"€100","339":"€339","159.75":"€159.8","219.5":"€219.5","279.25":"€279.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":338.1634326,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€338.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":254.40124024874999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€254.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":219.80623119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€219.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[100,159.75,219.5,279.25,339],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.35,175.8741102,189.3982204,202.9223306,216.4464408,229.970551,243.4946612,257.0187714,270.5428816,284.0669918,297.591102,311.11521220000003,324.6393224,{"y":338.1634326,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.35,169.43086463451922,176.51172926903845,183.59259390355768,190.67345853807691,197.75432317259614,204.83518780711537,211.9160524416346,218.99691707615384,226.07778171067307,233.1586463451923,240.23951097971153,247.32037561423076,{"y":254.40124024874999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.35,166.76971009153846,171.18942018307692,175.60913027461538,180.02884036615384,184.4485504576923,188.86826054923077,193.28797064076923,197.7076807323077,202.12739082384616,206.54710091538462,210.96681100692308,215.38652109846154,{"y":219.80623119,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":101.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.15,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.3,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.35,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >